Fampridine for the improvement of walking in multiple sclerosis
Fampridine (Fampyra) is a selective potassium channel blocker licensed for the improvement of walking in multiple sclerosis. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Dr Ruth Dobson discusses its potential role in the treatm...
Gespeichert in:
| Veröffentlicht in: | Prescriber (London, England) England), 2012-04, Vol.23 (7), p.12-16 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Fampridine (Fampyra) is a selective potassium channel blocker licensed for the improvement of walking in multiple sclerosis. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Dr Ruth Dobson discusses its potential role in the treatment of walking disability in multiple sclerosis. Copyright © 2012 Wiley Interface Ltd |
|---|---|
| ISSN: | 0959-6682 1931-2253 |
| DOI: | 10.1002/psb.890 |